期刊
JOURNAL OF PALLIATIVE MEDICINE
卷 20, 期 5, 页码 533-537出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/jpm.2016.0338
关键词
platelet-lymphocyte ratio; prognosis; terminal care
资金
- Senior-friendly Product R&D program - Ministry of Health and Welfare thorough the Korean Industry Development Institute [HI14C1435]
Background: An elevated platelet-lymphocyte ratio (PLR) is an indicator for worse outcomes in cancer, but its significance at the end of life remains unclear. Objective: This study aimed to investigate the value of PLR as an independent prognostic factor in terminally ill cancer patients. Methods: This retrospective cohort study included 312 terminal cancer patients and was conducted in a palliative care unit of a tertiary cancer center. Patient demographic data, clinical information, and laboratory values, including complete blood cell count, were obtained. Survival was analyzed using the Kaplan-Meier method and log-rank test. The Cox proportional hazards model was used to identify independent prognostic factors for survival. Results: Median survival was 16 days in patients with PLR >= 200 and 9 days in patients with PLR < 200 (p = 0.008). Results of multivariate analysis showed that the following factors predicted worse survival: poor performance status (adjusted hazard ratio [aHR], 2.16; 95% confidence interval [CI], 1.50-3.09), azotemia (aHR, 1.43; 95% CI, 1.01-2.02), hypoalbuminemia (aHR, 1.55; 95% CI, 1.07-2.26), hyperbilirubinemia (aHR, 1.67; 95% CI, 1.23-2.29), elevated lactate dehydrogenase (aHR, 1.58; 95% CI, 1.11-2.26), high neutrophillymphocyte ratio (aHR, 1.49; 95% CI, 1.09-2.04), and low PLR (aHR, 1.46; 95% CI, 1.08-1.97). Conclusion: Although elevated PLR indicates worse outcomes in patients with solid tumors, decreased PLR was an independent prognostic factor for poor survival in cancer patients at the end of life.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据